VITRAFY LIFE SCIENCES LIMITED (VFY)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

VFY

VFY - VITRAFY LIFE SCIENCES LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -0.02
Index: ALL-ORDS

Vitrafy Life Sciences develops cryopreservation technology for biological materials, combining freezing and thawing equipment with software to track and monitor stored samples.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.34

09 Nov
2026

-0.110

OPEN

$2.45

-4.49%

HIGH

$2.48

21,963

LOW

$2.34

TARGET
$4.97 112.4% upside
FNARENA'S MARKET CONSENSUS FORECASTS
VFY: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 25.2 - 30.5 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202420252026
EPS Basic xxxxxx-25.2
DPS All xxxxxx0.0
Sales/Revenue xxxxxx0.2 M
Book Value Per Share xxxxxx54.5
Net Operating Cash Flow xxxxxx-15.8 M
Net Profit Margin xxxxxx-9,584.18 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202420252026
Return on Capital Employed xxxxxx-46.29 %
Return on Invested Capital xxxxxx-45.93 %
Return on Assets xxxxxx-43.09 %
Return on Equity xxxxxx-46.29 %
Return on Total Capital xxxxxx-57.44 %
Free Cash Flow ex dividends xxxxxx-16.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202420252026
Short-Term Debt xxxxxx0 M
Long Term Debt xxxxxx0 M
Total Debt xxxxxx0 M
Goodwill - Gross xxxxxx-
Cash & Equivalents - Generic xxxxxx41 M
Price To Book Value xxxxxx5.52

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202420252026
Capex xxxxxx0.5 M
Capex % of Sales xxxxxx318.48 %
Cost of Goods Sold xxxxxx13 M
Selling, General & Admin. Exp & Other xxxxxx8 M
Research & Development xxxxxx-
Investments - Total xxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

29/10/2026

1

Speculative Buy

$4.85

107.26%

Vitrafy Life Sciences reported an increase of 76.6% in cash receipts in the first quarter. Cash costs increased 11.7% quarter on quarter. The main milestone in the near term is the FDA medical device listing, Bell Potter notes, targeted for the end of 2026.

The engineering phase is near completion and the main risk is whether the company and its civilian blood network partners can secure sufficient volumes to complete validation. Vitrafy expects to partner with more blood networks over the course of FY27, aiming for more than 50% of collection sites by FY28.

The broker remodels assumptions and the net result is a -5.8% reduction to valuation. Target is reduced to $4.85 from $5.15. Speculative Buy retained.

FORECAST
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -28.20 cents.
Bell Potter forecasts a full year FY28 EPS of minus -27.20 cents.

Ord Minnett

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

VFY STOCK CHART

FNArena News on VFY

1
Rudi’s View: Quality At Home, Value Abroad

Oct 22 2026 - Rudi's View
2
Vitrafy Eyes US Blood Breakthrough

Oct 06 2026 - Small Caps
3
Rudi’s View: Post-August Stock Picks & Best Buys

Sep 10 2026 - Rudi's View
4
FNArena Corporate Results Monitor – 05-08-2026

Aug 05 2026 - Australia
5
FNArena Corporate Results Monitor – 05-02-2026

Feb 05 2026 - Australia